SCHEMBL1445804

SCHEMBL1445804

CC([C]=O)c1ccc(C(=N)N)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPN1 P15169 1/20 0.45
CPB2 Q96IY4 1/20 0.45
LMNA P02545 2/20 0.43
PLAU P00749 2/20 0.43
MASP2 O00187 1/20 0.43
THPO P40225 1/20 0.43
PRSS1 P07477 5/20 0.42
PRSS3 P35030 5/20 0.42
PRSS2 P07478 4/20 0.42
F2 P00734 4/20 0.42
APEX1 P27695 1/20 0.42
ST14 Q9Y5Y6 2/20 0.41
PRMT5 O14744 1/20 0.41
PRMT1 Q99873 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
F10 P00742 2/20 0.40
F12 P00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10585660 0.78 TYR (0.35)
SCHEMBL1505347 0.77 HTT (0.61) CPN1CPB2LMNAPLAUMASP2
SCHEMBL14119117 0.77 KIF11 (0.44) PRSS1PRSS3PRSS2F2ST14
SCHEMBL8169323 0.74 CPN1 (0.46) CPN1CPB2LMNAPLAUMASP2
SCHEMBL12792667 0.73 CPN1 (0.57) CPN1CPB2LMNAPRSS1PRSS3
SCHEMBL582044 0.73 ESR1 (0.54) LMNATHPOALDH1A1HPGDCYP2C19
SCHEMBL5987630 0.73 MEN1 (0.38) LMNAALDH1A1
SCHEMBL11835373 0.72 ALDH1A1 (0.52) LMNATHPOALDH1A1HPGDHSD17B10
SCHEMBL537030 0.71 LMNA (0.77) LMNAPLAUMASP2THPOPRSS1
SCHEMBL23049360 0.71 PRSS1 (0.48) CPN1CPB2LMNAPLAUMASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366786-A2 Cytokine receptor modulators and uses thereof VALORISATION HSJ, Société en Commandite (CA) 2011-09-21 EP claimed
EP-2288621-A2 IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF Valorisation HSJ, Societe en Commandite (CA) 2011-03-02 EP claimed
EP-1885855-A4 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF VALORISATION HSJ SOC EN COMMAN (CA) 2009-03-04 EP claimed
US-20090048161-A1 Cytokine receptor modulators and uses thereof VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) 2009-02-19 US claimed
WO-2009007849-A2 IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) 2009-01-15 WO claimed
EP-1751175-A4 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT VALORISATION RECH SOC EN COMMA (CA) 2008-12-17 EP claimed
EP-1885855-A2 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF VALORISATION HSJ, Société en Commandite (CA) 2008-02-13 EP claimed
EP-1751175-A1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT Valorisation-Recherche, Société en Commandite (CA) 2007-02-14 EP claimed
WO-2007004060-A2 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) 2007-01-11 WO claimed
US-20060094663-A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2006-05-04 US claimed
WO-2005105830-A1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2005-11-10 WO claimed
US-8802818-B2 Prostaglandin-F2 alpha receptor modulators and uses thereof LUBELL WILLIAM D (CA) 2014-08-12 US disclosed
US-8618054-B2 Interleukin-1 receptor antagonists, compositions, and methods of treatment Valorisation-Rechereche Société en Commandite (CA) 2013-12-31 US disclosed
US-20120309690-A1 PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF LUBELL WILLIAM D (CA) 2012-12-06 US disclosed
EP-1751175-B1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT VALORISATION RECH SOC EN COMMANDITE (CA) 2012-07-25 EP disclosed
EP-1885855-A2 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF VALORISATION HSJ, Société en Commandite (CA) 2008-02-13 EP disclosed
EP-1751175-A1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT Valorisation-Recherche, Société en Commandite (CA) 2007-02-14 EP disclosed
WO-2007004060-A2 CYTOKINE RECEPTOR MODULATORS AND USES THEREOF VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) 2007-01-11 WO disclosed
US-20060094663-A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2006-05-04 US disclosed
WO-2005105830-A1 INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309690-A1 PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF PTGFR, PTGER1, PTGER2 CPN1 2942/4885CPB2 1612/4885LMNA 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.